Observational study of spinal muscular atrophy type I and implications for clinical trials

Richard S. Finkel, Michael P. McDermott, Petra Kaufmann, Basil T. Darras, Wendy K. Chung, Douglas M. Sproule, Peter B. Kang, A. Reghan Foley, Michelle L. Yang, William B. Martens, Maryam Oskoui, Allan M. Glanzman, Jean Flickinger, Jacqueline Montes, Sally Dunaway, Jessica O'Hagen, Janet Quigley, Susan Riley, Maryjane Benton, Patricia A. RyanMegan Montgomery, Jonathan Marra, Clifton Gooch, Darryl C. De Vivo

Research output: Contribution to journalArticlepeer-review

281 Scopus citations

Abstract

Objectives: Prospective cohort study to characterize the clinical features and course of spinal muscular atrophy type I (SMA-I). Methods: Patients were enrolled at 3 study sites and followed for up to 36 months with serial clinical, motor function, laboratory, and electrophysiologic outcome assessments. Intervention was determined by published standard of care guidelines. Palliative care options were offered. Results: Thirty-four of 54 eligible subjects with SMA-I (63%) enrolled and 50% of these completed at least 12 months of follow-up. The median age at reaching the combined endpoint of death or requiring at least 16 hours/day of ventilation support was 13.5 months (interquartile range 8.1-22.0 months). Requirement for nutritional support preceded that for ventilation support. The distribution of age at reaching the combined endpoint was similar for subjects with SMA-I who had symptom onset before 3 months and after 3 months of age (p 5 0.58). Having 2 SMN2 copies was associated with greater morbidity and mortality than having 3 copies. Baseline electrophysiologic measures indicated substantial motor neuron loss. By comparison, subjects with SMA-II who lost sitting ability (n510) had higher motor function, motor unit number estimate and compound motor action potential, longer survival, and later age when feeding or ventilation support was required. The mean rate of decline in The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders motor function scale was 1.27 points/year (95% confidence interval 0.21-2.33, p 5 0.02). Conclusions: Infants with SMA-I can be effectively enrolled and retained in a 12-month natural history study until a majority reach the combined endpoint. These outcome data can be used for clinical trial design.

Original languageEnglish (US)
Pages (from-to)810-817
Number of pages8
JournalNeurology
Volume83
Issue number9
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Observational study of spinal muscular atrophy type I and implications for clinical trials'. Together they form a unique fingerprint.

Cite this